AusperBio's Hepatitis B Drug Advances to Late-Stage in China

AusperBio announced on 22 July that China's Centre for Drug Evaluation (CDE) approved Phase III trials for its antisense oligonucleotide (ASO) drug AHB-137, targeting functional cure in HBeAg-negative chronic hepatitis B (CHB) patients. The randomised double-blind study will evaluate 300 mg doses over 24 weeks in patients on stable nucleos(t)ide analogue therapy. AHB-137 previously received breakthrough therapy designation (BTD) in 2024 and demonstrated strong efficacy in Phase II trials.

CHB affects 290 million globally, including 75 million in China, often leading to cirrhosis and liver cancer. AHB-137, developed using AusperBio's proprietary Med-Oligo platform, represents a potential first-in-class non-conjugated ASO therapy. CEO Guofeng Cheng noted the trial approval marks a milestone toward achieving HBV functional cure, while CSO Chengyong Yang highlighted plans for rapid trial initiation to address unmet needs.

According to PharmCube's NextBiopharm® database, there are 200 CHB therapies in the global pipeline, including 7 ASOs. Click here to request a free trial for NextBiopharm®.

Subscribe to our newsletter
A weekly newsletter curated for industry professionals. Join thousands of fellow subscribers for free
Subscribe for Free
Daily News
AbbVie Immunology Duo Skyrizi/Rinvoq Delivers USD 11.6b in H1'25
2025-08-02
BMS H1'25 Revenue hits USD 23.5b Driven by Opdivo's USD 4.8b
2025-08-02
Hrain's CD19 CAR-T Therapy Approved as China's Fourth for Lymphoma
2025-08-02
Sanofi Reports EUR 19.9b H1 Revenue With Dupixent Topping EUR 7b
2025-08-02
AllianThera Partners with Dr. Falk Pharma on Novel UC Drug
2025-08-01
Latest Report
From Reliance to Defiance: A Decade-Long Panorama of China's Innovative Drug Transactions
Details